Search results for "ca125"

showing 8 items of 8 documents

Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure

2015

AIM:Galectin-3 (Gal-3) and carbohydrate antigen 125 (CA125) have emerged as robust prognostic biomarkers in heart failure. Experimental data have also suggested a potential molecular interaction between CA125 and Gal-3; however, the biological and clinical relevance of this interaction is still uncertain. We sought to evaluate, in patients admitted for acute heart failure, the association between plasma Gal-3 with all-cause mortality and the risk for rehospitalizations among high and low levels of CA125. METHODS AND RESULTS: We included 264 consecutive patients admitted for acute heart failure to the Cardiology Department in a third-level center. Both biomarkers were measured on admission. …

Maleendocrine system diseasesGalectin 3lcsh:MedicineRisk FactorsBlood plasmaANTIGEN CARBOHYDRATE 125lcsh:ScienceAged 80 and overMultidisciplinaryca125Mortality rateBlood Proteins//purl.org/becyt/ford/3.1 [https]Middle AgedPrognosisMedicina BásicaGalectin-3Female//purl.org/becyt/ford/3 [https]Research Articlemedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDcontributesGalectinsInmunologíaPatient ReadmissionAntigenInternal medicinemedicineHumanssurfaceClinical significanceIn patientIntensive care medicineAgedProportional Hazards ModelsHeart FailureGALECTIN-3business.industryProportional hazards modellcsh:Rassociationmedicine.diseaseACUTE HEART FAILUREstatin therapyinflammationCA-125 AntigenHeart failurecellslcsh:QbusinessBiomarkersFollow-Up Studies
researchProduct

Evaluation of serum CA 125 levels in patients with pelvic pain related to endometriosis.

2007

The aim of the study was to investigate the clinical value of the serum CA 125 level for diagnosing and determining the severity of endometriosis and pelvic pain associated with endometriosis. Eighty-six women who underwent operative laparoscopy were enrolled. Sixty-nine women with endometriosis and 17 without endometriosis participated in this study. In all of the patients, endometriosis was diagnosed and classified into stages according to the Revised American Fertility Society (R-AFS) classification. The mean serum CA 125 levels were determined in each patient. We also investigated the relationship between serum CA 125 concentration and the intensity of dysmenorrhea and dyspareunia in t…

0301 basic medicineAdultCancer Researchmedicine.medical_specialtyClinical BiochemistryCa 125 antigenEndometriosisEndometriosisPelvic PainSensitivity and SpecificityGastroenterologyAsymptomaticendometriosis ca125.Pathology and Forensic Medicine03 medical and health sciences0302 clinical medicineGynecologic Surgical ProceduresSettore MED/38 - Pediatria Generale E SpecialisticaDysmenorrheaStatistical significanceInternal medicineHumansMedicineIn patientGynecologybusiness.industryPelvic painMiddle Agedmedicine.disease030104 developmental biologyDyspareuniaOncology030220 oncology & carcinogenesisCA-125 AntigenClinical valueFemaleLaparoscopyOperative laparoscopymedicine.symptombusiness
researchProduct

Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure

2021

INTRODUCTION: We aimed to evaluate the trajectory of two surrogates of fluid overload -antigen carbohydrate 125 (CA125) and amino-terminal pro-brain natriuretic peptide (NT-proBNP)- after the addition of oral empagliflozin to usual care in a cohort of patients with chronic heart failure (CHF) and type 2 diabetes (T2D). METHODS AND RESULTS: From October 2015 to February 2019, 60 ambulatory patients with CHF and T2D were retrospectively included. The primary endpoint was to assess the longitudinal trajectory of plasma levels of CA125 and NT-proBNP after empagliflozin initiation. Changes in quantitative variables were evaluated using linear mixed regression. Median CA125 and NT-proBNP at basel…

medicine.medical_specialtyendocrine system diseasesType 2 diabetes030204 cardiovascular system & hematologyCA12503 medical and health sciences0302 clinical medicineGlucosidesEmplagliflozinInterquartile rangeLongitudinal trajectoriesInternal medicineNatriuretic Peptide BrainmedicineEmpagliflozinClinical endpointHumansSGLT2icardiovascular diseases030212 general & internal medicineBenzhydryl CompoundsRetrospective StudiesHeart FailureSurrogate endpointbusiness.industrymedicine.diseasePeptide FragmentsDiabetes Mellitus Type 2Heart failureNTproBNPAmbulatoryCohortCardiologyCardiology and Cardiovascular MedicinebusinessBiomarkersInternational Journal of Cardiology
researchProduct

Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure

2022

Introduction and objectives: Carbohydrate antigen 125 (CA125) has been shown to be useful for risk stratification in patients admitted with acute heart failure (AHF). We sought to determine a CA125 cutpoint for identifying patients at low risk of 1-month death or the composite of death/HF readmission following admission for AHF.Methods: The derivation cohort included 3231 consecutive patients with AHF. CA125 cutoff values with 90% negative predictive value (NPV) and sensitivity up to 85% were identified. The adequacy of these cutpoints and the risk of 1-month death/HF readmission was then tested using the Royston-Parmar method. The best cutpoint was selected and externally validated in a co…

medicine.medical_specialtyOptimal cutoffAntígeno carbohidrato 125MONOCLONAL-ANTIBODYendocrine system diseasesCarbohydratesAftercareInsuficiencia cardiaca aguda030204 cardiovascular system & hematologyWorsening Heart FailureCA12503 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCutoffIn patientOutcomeHeart FailureNATRIURETIC PEPTIDEbusiness.industryMORTALITYPronósticoGeneral MedicineCongestiónPrognosismedicine.diseasePredictive valuePatient Dischargefemale genital diseases and pregnancy complicationsAntígeno carbohidrato 125; CA125; Carbohydrate antigen 125; Congestion; Congestión; Insuficiencia cardiaca aguda; Outcome; Pronóstico; Worsening Heart Failure; Acute Disease; CA-125 Antigen; Carbohydrates; Humans; Patient Discharge; Prognosis; Aftercare; Heart FailureCarbohydrate antigen 125CA-125 AntigenHeart failureAcute DiseaseCohortRisk stratificationCongestionbusinessCarbohydrate antigenRevista Española de Cardiología (English Edition)
researchProduct

Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure.

2021

BACKGROUND: The optimal length of stay (LOS) in patients hospitalized for acute heart failure (AHF) remains controversial. Plasma antigen carbohydrate 125 (CA125) has emerged as a reliable proxy of congestion. We aimed to evaluate whether there is a differential impact of LOS on the risk of 6-month AHF readmission across CA125 levels. METHODS: This is a retrospective study that included 1,387 patients discharged for AHF in two third-level centers. CA125 was measured 48±24h after admission. The association between CA125 and LOS with the risk of subsequent AHF readmission at 6 months was analyzed by Cox regression analysis accounting for death as a competing event. RESULTS: The median (IQR) a…

medicine.medical_specialtyMultivariate analysisendocrine system diseasesacute heart failureCarbohydrates030204 cardiovascular system & hematologyVentricular Function LeftCA12503 medical and health sciences0302 clinical medicinelength of stayAntigenInternal medicineInternal MedicineHumansMedicineIn patient030212 general & internal medicineAgedRetrospective StudiesDifferential impactAged 80 and overHeart FailureEjection fractionbusiness.industryProportional hazards modelStroke VolumeRetrospective cohort studyLength of StayPrognosismedicine.diseasefemale genital diseases and pregnancy complicationsHeart failureAcute DiseaseFemalebusiness
researchProduct

CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure

2021

Abstract Background Intrarenal venous flow (IRVF) measured by Doppler ultrasound has gained interest as a potential surrogate marker of renal congestion and adverse outcomes in heart failure. In this work, we aimed to determine if antigen carbohydrate 125 (CA125) and plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP) are associated with congestive IRVF patterns (i.e., biphasic and monophasic) in acute heart failure (AHF). Methods and results We prospectively enrolled a consecutive cohort of 70 patients hospitalized for AHF. Renal Doppler ultrasound was assessed within the first 24-h of hospital admission. The mean age of the sample was 73.5 ± 12.3 years; 47.1% were female, and…

medicine.medical_specialtymedicine.drug_classCarbohydrates030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineVenous flow03 medical and health sciencesCA1250302 clinical medicineInterquartile rangeIntrarrenal Doppler ultrasoundInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumans030212 general & internal medicineHeart FailureOriginal Scientific PaperSurrogate endpointbusiness.industryCardiorenalMembrane ProteinsAcute heart failureGeneral Medicinemedicine.diseasePrognosisPeptide FragmentsROC CurveHeart failureCA-125 AntigenCohortNTproBNPCardiologyCongestionFemaleDoppler ultrasoundCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionBiomarkers
researchProduct

Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation

2013

ObjectivesThis study sought to predict the value of tumor marker carbohydrate antigen 125 (CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a composite endpoint of death, admission for heart failure, myocardial infarction, and stroke (major adverse cardiac events [MACE]).BackgroundRisk stratification after TAVI remains challenging. The use of biomarkers in this setting represents an unmet need.MethodsCA125 was measured in 228 patients before and after TAVI. The association with outcomes was assessed using parametric Cox regression and joint modeling for baseline and longitudinal analyses, respectively. CA125 was evaluated as logarithm transforma…

Malemedicine.medical_specialtyCardiac CatheterizationTime FactorsAortic Valve InsufficiencyMyocardial InfarctionKaplan-Meier EstimateRisk AssessmentCA125Interquartile rangeRisk FactorsInternal medicineMedicineHumansMyocardial infarctionLongitudinal StudiesRegistriesStroketranscatheter aortic valve implantationTumor markerAgedProportional Hazards ModelsAged 80 and overHeart FailureHeart Valve Prosthesis ImplantationProportional hazards modelbusiness.industryMembrane ProteinsAortic Valve Stenosismedicine.diseasejoint modelingHospitalizationStrokeLogistic ModelsTreatment OutcomeCardiovascular DiseasesHeart failureCA-125 AntigenMultivariate AnalysisCardiologybiomarkerBiomarker (medicine)FemaleprognosisbusinessCardiology and Cardiovascular MedicineMaceBiomarkersJACC: Cardiovascular Interventions
researchProduct

Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure

2020

Abstract Background Carbohydrate antigen 125 (CA125) and B-type natriuretic peptides are surrogate markers of congestion in patients with acute heart failure (AHF). The aim of the study was to assess the association between CA125 and NT-proBNP and congestion parameters in patients with AHF. Methods and results Prospective multicentre observational study that included 191 patients hospitalised for AHF. We recorded the presence of pleural effusion, peripheral oedema and inferior vena cava (IVC) diameter during the first 24–48 h after admission and evaluated their independent association with CA125 concentrations and the amino-terminal fraction of pro-B-type natriuretic peptide (NT-proBNP). Th…

Malemedicine.medical_specialtyendocrine system diseasesmedicine.drug_classPleural effusionPeripheral edemaInferior vena cavaVentricular Function LeftInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumansIn patientProspective StudiesAgedAged 80 and overHeart FailureEjection fractionbusiness.industryStroke VolumeMiddle AgedPrognosismedicine.diseasePeptide Fragmentsmedicine.veinHeart failureCardiologySerum ca125Femalemedicine.symptombusinessBiomarkersMedicina Clínica (English Edition)
researchProduct